Skip to content

Similar papers

Open access Oct 2026

Safety signals of tocilizumab in pediatric patients: A real-world pharmacovigilance analysis based on the FAERS database with network pharmacology insights

ABSTRACT Tocilizumab, a humanized monoclonal antibody targeting the interleukin-6 receptor, is widely used in immune-mediated diseases, yet its real-world safety in pediatric populations remains insufficiently characterized. This retrospective pharmacovigilance study analyzed adverse event (AE) reports from the U.S. Fo...

Gang Wu, Xue-Qing Ma, Bin Zhu et al. · 1 citation
Open access Oct 2026

Glucocorticoid-centered drug spectrum of non-jaw osteonecrosis, a FAERS pharmacovigilance study with independent validation in Canada Vigilance and JADER

Objective To distinguish jaw misclassification and litigation-related reporting from non-jaw osteonecrosis signals and define their reproducible spectrum. Methods We analyzed 20,690,895 deduplicated Food and Drug Administration Adverse Event Reporting System (FAERS) reports (2004Q1–2026Q2), using report-level adjudicat...

Li-Sheng Qi, Yu-Lan Qiu, Xiao-Bin Wang et al. · 0 citations
Open access Oct 2026

A real-world pharmacovigilance study of FDA adverse event reporting system events for bictegravir/emtricitabine/tenofovir alafenamide

These pharmacovigilance signals merit clinical awareness, particularly regarding metabolic monitoring, virologic/immunologic parameters, and pregnancy exposure reporting, however, these findings are exploratory and should not be interpreted as confirmed causal associations.

Ying Liu, Lei-Dan Zhang, Xin Li et al. · 0 citations
Open access Sep 2026

Multinational pharmacovigilance assessment of drug-associated esophageal ulceration and perforation: evidence from FAERS, JADER, and Canada Vigilance

Drug-associated esophageal ulceration and perforation are uncommon but clinically serious adverse events. This study characterized post-marketing reporting patterns for these events across three spontaneous reporting systems. Reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), Jap...

Li-Hua Zhang, Xin-Chi Luan, Cai-Qi Liu et al. · 0 citations
Review Open access Sep 2026

Gastrointestinal and skin safety evaluation of pirfenidone versus nintedanib: an analysis of real-world pharmacovigilance and randomized controlled trials.

This study compares their safety profiles using real-world pharmacovigilance data and meta-analysis to guide clinical use. The gastrointestinal disorders and skin-related ADRs listed in the latest instructions for pirfenidone and nintedanib were systematically reviewed and subsequently analyzed using the FDA Adverse Ev...

Xin-Ping Yang, Yu-Ting Wang, Xijier Qiaolongbatu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.